Evidence map›Paper›PMID 25825704›Full record

ArticleJournal of immunology research2014

CD8+ TIL recruitment may revert the association of MAGE A3 with aggressive features in thyroid tumors.

Mariana Bonjiorno Martins, Marjory Alana Marcello, Fernando de Assis Batista, Lucas Leite Cunha, Elaine Cristina Morari, Fernando Augusto Soares, José Vassallo, Laura Sterian Ward

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mariana Bonjiorno MartinsLaboratory of Cancer Molecular Genetics, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 126 Tessália Vieira de Camargo Street, Barão Geraldo, 13083-887 Campinas, SP, Brazil.
Marjory Alana MarcelloLaboratory of Cancer Molecular Genetics, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 126 Tessália Vieira de Camargo Street, Barão Geraldo, 13083-887 Campinas, SP, Brazil.
Fernando de Assis BatistaLaboratory of Cancer Molecular Genetics, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 126 Tessália Vieira de Camargo Street, Barão Geraldo, 13083-887 Campinas, SP, Brazil.ORCID 0000-0001-5479-5329
Lucas Leite CunhaLaboratory of Cancer Molecular Genetics, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 126 Tessália Vieira de Camargo Street, Barão Geraldo, 13083-887 Campinas, SP, Brazil.
Elaine Cristina MorariLaboratory of Cancer Molecular Genetics, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 126 Tessália Vieira de Camargo Street, Barão Geraldo, 13083-887 Campinas, SP, Brazil ; Department of Biological Sciences and Health, State University of Roraima (UERR), Rua Sete de Setembro 231, 69306-530 Boa Vista, RR, Brazil.
Fernando Augusto SoaresDepartment of Pathology, AC Camargo Hospital, Antonio Prudente Foundation, 211 Professor Antonio Prudente Street, 01509-010 São Paulo, SP, Brazil.
José VassalloDepartment of Pathology, AC Camargo Hospital, Antonio Prudente Foundation, 211 Professor Antonio Prudente Street, 01509-010 São Paulo, SP, Brazil ; Laboratory of Investigative and Molecular Pathology, CIPED, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 126 Tessália Vieira de Camargo Street, 13083-887 Campinas, SP, Brazil.
Laura Sterian WardLaboratory of Cancer Molecular Genetics, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 126 Tessália Vieira de Camargo Street, Barão Geraldo, 13083-887 Campinas, SP, Brazil.
Universidade Estadual de Campinas (UNICAMP) · BRAC Camargo Hospital · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to investigate a possible role of MAGE A3 and its associations with infiltrated immune cells in thyroid malignancy, analyzing their utility as a diagnostic and prognostic marker. MATERIALS AND

methodsWe studied 195 malignant tissues: 154 PTCs and 41 FTCs; 102 benign tissues: 51 follicular adenomas and 51 goiter and 17 normal thyroid tissues. MAGE A3 and immune cell markers (CD4 and CD8) were evaluated using immunohistochemistry and compared with clinical pathological features.

resultsThe semiquantitative analysis and ACIS III analysis showed similar results. MAGE A3 was expressed in more malignant than in benign lesions (P < 0.0001), also helping to discriminate follicular-patterned lesions. It was also higher in tumors in which there was extrathyroidal invasion (P = 0.0206) and in patients with stage II disease (P = 0.0107). MAGE A3+ tumors were more likely to present CD8+ TIL (P = 0.0346), and these tumors were associated with less aggressive features, that is, extrathyroidal invasion and small size. There was a trend of MAGE A3+ CD8+ tumors to evolve free of disease.

conclusionWe demonstrated that MAGE A3 and CD8+ TIL infiltration may play an important role in malignant thyroid nodules, presenting an interesting perspective for new researches on DTC immunotherapy.

Indexed as

Adenocarcinoma, FollicularAdolescentAdultAgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorCarcinogenesisCD4 AntigensCD8 AntigensCell MovementDisease ProgressionFemaleHumansImmunotherapyLymphocytes, Tumor-InfiltratingAntigens, NeoplasmBiomarkers, TumorCD4 AntigensCD8 AntigensMAGEA3 protein, humanNeoplasm Proteins

Identifiers

PMID25825704
PMCPMC4235601
OpenAlexW2315908342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.